Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy
Clinical and Molecular Hepatology · 2025
DOI: 10.3350/cmh.2025.0292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Moana Witte und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany. Hauptthemen laut MEDLINE: Liver Cirrhosis, Antiviral Agents, Hepatitis C, Chronic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: German Federal Ministry of Education and Research, German Center for Infection Research, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Background/Aims: Hepatitis C virus (HCV) infection remains a global health challenge, leading to chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). Despite the high efficacy of direct-acting antiviral therapy in achieving sustained virologic response (SVR), concerns persist regarding long-term immune alterations and residual risks, particularly in cirrhotic patients.
Methods
This study investigates 75 soluble immune mediator (SIM) profiles in 102 chronic HCV patients, stratified by cirrhosis status, at therapy initiation, end of treatment, and long-term follow-up (median 96 weeks). Findings were compared with 51 matched healthy controls and validated in an independent cohort of 47 cirrhotic patients, 17 of whom developed HCC.
Results
We observed significant SIM alterations at baseline, with cirrhotic patients displaying a more profoundly dysregulated inflammatory milieu. Despite an overall decline in inflammatory markers following SVR, persistent alterations were evident, particularly in cirrhotic patients. Notably, those with liver stiffness exceeding 14 kPa exhibited sustained inflammatory dysregulation, correlating with liver elastography values. Key SIM such as interleukin (IL)-6, IL-8, urokinase plasminogen activator, and hepatocellular growth factor remained elevated and were associated with HCC development. Network analysis highlighted their roles in liver fibrosis, regeneration, and carcinogenesis.
Conclusions
These findings underscore the importance of early antiviral intervention to prevent cirrhosis-related sequelae. Future studies should explore the mechanistic pathways linking chronic inflammation, fibrosis, and oncogenesis to identify predictive biomarkers and novel therapeutic targets. Addressing persistent immune alterations post-HCV clearance may improve long-term outcomes, particularly in patients with advanced liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School (MHH), Hannover, Germany.
- TWINCORE Center of Experimental and Clinical Infection Research, Hannover, Germany.
- German Center for Infection Research (DZIF), Partner-site Hannover-Braunschweig, Hannover, Germany.
- Center for Individualized Infection Medicine (CiiM), Hannover, Germany.
- Division Data Science in Biomedicine, Peter L. Reichertz Institute for Medical Informatics of Technische Universität Braunschweig and Hannover Medical School, Braunschweig, Germany.
- Braunschweig Integrated Centre for Systems Biology (BRICS Technische Universität Braunschweig), Braunschweig, Germany.
Förderung
- German Federal Ministry of Education and Research
- German Center for Infection Research
- Deutsche Forschungsgemeinschaft
- Else Kröner-Fresenius-Stiftung
Zitieren
APA
Witte, M., Oltmanns, C., Tauwaldt, J., Schmaus, H., Mischke, J., Grabert, G., Bretthauer, M., Roesner, L. M., Werfel, T., Deterding, K., Maasoumy, B., Wedemeyer, H., Kacprowski, T., Kraft, A. R. M., & Cornberg, M. (2025). Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2025.0292
Vancouver
Witte M, Oltmanns C, Tauwaldt J, Schmaus H, Mischke J, Grabert G, et al. Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2025.0292
BibTeX
@article{Witte2025,
author = {Witte, Moana and Oltmanns, Carlos and Tauwaldt, Jan and Schmaus, Hagen and Mischke, Jasmin and Grabert, Gordon and Bretthauer, Mara and Roesner, Lennart M and Werfel, Thomas and Deterding, Katja and Maasoumy, Benjamin and Wedemeyer, Heiner and Kacprowski, Tim and Kraft, Anke R M and Cornberg, Markus},
title = {Distinct inflammatory imprint in non-cirrhotic and cirrhotic patients before and after direct-acting antiviral therapy},
journal = {Clinical and Molecular Hepatology},
year = {2025},
doi = {10.3350/cmh.2025.0292}
}
EUVIMED